JAGSONPAL PHARMACEUTICALS
|
|
BOM : 507789     NSE : JAGSNPHARM     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Oct 07,2024 |
Price(EOD): ₹ 403.40
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 1,069.01 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
JAGSONPAL PHARMACEUTICALS | -3.8% | -3.4% | 2.4% |
SUN PHARMACEUTICAL INDUSTRIES | -1.1% | 4.4% | 67.3% |
CIPLA | -1.8% | -0.2% | 37.2% |
DR REDDYS LABORATORIES | -2.3% | -1.4% | 21.5% |
ZYDUS LIFESCIENCES | -1.6% | -5.8% | 73.2% |
DIVIS LABORATORIES | -0.8% | 5.4% | 45.7% |
FUNDAMENTAL ANALYSIS OF JAGSONPAL PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF JAGSONPAL PHARMACEUTICALS
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
52.6
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 20.31 Cr
[Latest Qtr - Jun2024 - Standalone Results ] 6.27
P/B Calculated based on Book Value of Rs 170.33 Cr
[Latest Year - Mar2024 - Standalone Results ] 5.09
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Jun2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
233% 383% 873% |
SHARE PRICE MOMENTUM OF JAGSONPAL PHARMACEUTICALS
JAGSONPAL PHARMACEUTICALS vs SENSEX
DEBT OF JAGSONPAL PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0 0 - |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF JAGSONPAL PHARMACEUTICALS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF JAGSONPAL PHARMACEUTICALS
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
41.28% 283.59% 56.75% 50.16% |
2.14% 18.54% -29.54% -28.75% |
QtrlyTrend |
4 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
JAGSONPAL PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about JAGSONPAL PHARMACEUTICALS
Is JAGSONPAL PHARMACEUTICALS good for long term investment?
As on Oct 07,2024, the Fundamentals of JAGSONPAL PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of JAGSONPAL PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is JAGSONPAL PHARMACEUTICALS UnderValued or OverValued?
As on Oct 07,2024, JAGSONPAL PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of JAGSONPAL PHARMACEUTICALS ?
As on Oct 07,2024, the Intrinsic Value of JAGSONPAL PHARMACEUTICALS is Rs. 83.59 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 121.17
Fair Value [Median EV / Sales Model] : Rs. 83.59
Fair Value [Median Price / Sales Model] : Rs. 41.44
Estimated Median Fair Value of JAGSONPAL PHARMACEUTICALS : Rs. 83.59
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.